The primary objective of this study was to determine the effect of treatment with dovitinib in combination with fulvestrant vs placebo plus fulvestrant on progression-free survival (PFS) in postmenopausal patients with HR+, HER2− breast cancer that had progressed during or after prior endocrine therapy in all evaluable patients, regardless of FGF pathway amplification status, and in patients with FGF pathway amplification (as measured by qPCR using a cutoff of at least six copies of FGFR1, FGFR2, or FGF3). The gene discussed is FGFR2; the disease is breast carcinoma.